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Results: 80/160 patients had a confirmed LE-DVT. There was a
significant difference in all biomarkers among those patients with LE-DVT.
(Table I) When Wells score 2, sPsel could rule LE-DVT with a specificity
of 96% and a PPV of 89%, which was more accurate thanWells score2 and
D-dimer (specificity 65% and PPV 71%). (Table II) When Well’s score was
2, D-dimer was superior to sPsel for excluding the diagnosis of LE-DVT
(sensitivity 100%, NPV 100% vs. sensitivity 90%, NPV 77%). The use of
additional biomarkers did not increase the specificity/sensitivity for diagnos-
ing LE-DVT. Using a combination of Wells score, D-dimer, and sPsel we
could correctly diagnose LE-DVT in 27% (43/160) of patients without the
use of imaging.
Conclusions: In validating our previous study, we have demonstrated,
in the setting of Wells score 2, sPsel is an excellent biomarker rule in
LE-DVT. Different from our derivation cohort, D-dimer and a Wells score
2 was more sensitive at excluding a diagnosis of LEDVT than sPsel and a
Wells score 2. Together, Wells score, sPsel, and D-dimer can both rule in
and exclude LE-DVT.




Positive LEDVT (95% confidence
intervals) P value
Female gender n
(%) 53 (66%) 34 (43%) .002
Age 53.2 years (50.2-56.1) 57.6 years (54.4-60.7) .046
Wells score 1.6 (1.4-1.8) 3.0 (2.6-3.3) .001
D-Dimer (ng/mL) 986.4 ng/mL (756.5-1216.3) 6268.4 ng/mL (5356.1-7180.7) .001
sPsel (ng/mL) 57.2 ng/mL (50.8-63.6) 78.4 ng/mL (70.8-85.9) .001
CRP (	g/mL) 1.34 	g/mL (0.65-2.03) 5.74 	g/mL (4.22-7.25) .001
vWF (% activity) 113.3% (95.3-131.3) 151.7% (134.6-168.8) .002
ADAMTS-13 (%
activity) 102% (97-106) 91% (86-95) .001













sPsel ( 90ng/mL) 
Wells score ( 2) 96% (88.7-99%) 31% (21.6-42.7%) 89% 58%
D-dimer ( 500ng/
mL) Wells score
(  2) 65% (53.4-75.1%) 84% (73.4-90.7%) 71% 80%
sPsel (60ng/mL) 
Wells score (2) 34% (23.8-45.3%) 90% (80.7-95.3) 58% 77%
D-dimer (500ng/
mL) Wells score
(2) 32% (22.7-44%) 100% (94.3-100%) 60% 100%
Deep Venous Thrombosis After Abdominal Aneurysm Repair
E. Xenos, D. Davenport, University of Kentucky Medical Center, Lexing-
ton, Ky
Objective: Thromboprophylaxis guidelines after abdominal aortic an-
eurysm repair are scarce. The objective of this study was to examine venous
thromboembolism (VTE) rates, timing and risk factors after nonruptured
open or endoluminal (ELG) Abdominal Aortic Aneurysm repair.
Methods: A systematic study of patients undergoing AAA repair was
performed. We queried the ACS NSQIP dataset from 2005-2009 for AAA
repairs using [CPT] and [ICD-9] codes. We excluded emergent/ruptured
AAA operations. Forward stepwise multivariable logistic regression of all
30-day VTE was performed.
Results:Our query yielded 12,469 patients. The mean age was 73.2
8.7 (s.d.) years and 2466 (19.8%) were female. The DVT rate within 30 days
of operation was 0.9% (n106) and the PE rate was 0.3% (n36). Diagnosis
of both was rare (n7) and the combined DVT or PE rate (VTE) was 1.1%
(n135). Thirty-day mortality was 1.9% (238/12,469) and VTE was asso-
ciated with increased 30-day mortality from 1.9% (232/12,102) in patients
without VTE to 4.4% (6/135) in patients with VTE (Chi-square p .035).
Thirty-percent (40/135) of treated VTEs were diagnosed after surgical
discharge. The median postoperative days to VTE diagnosis was 8 (inter-
quartile range, 4 to 15 days). Multivariable forward stepwise logistic regres-
sion yielded only four independent ACS NSQIP preoperative predictors of
VTE. They are shown in Table I by their order of entry into the model (and
therefore importance). This is after consideration of over fifty clinical risk
variables. Intraoperative risk factors are shown in Table II. After adjustment,
open repair had higher risk for VTE (OR, 1.46; 95% CI, 0.93-2.30) but this
was no longer statistically significant, p  .104.
Risk factors identified were ASA class 4-5(odds ratio[OR] 1.77,
P.002), operative duration4hrs(OR 2.33, P.14) and intraoperative
blood transfusion. Operative duration and transfusion were both risk factors
and increased with increasing “dose”.
Discussion: Although VTE after AAA repair was infrequent, it was
associated with higher mortality. Open AAA repair increases risk for post-
operative VTE as compared to ELG. It was surprising to find that 1/3 of
VTE’s were diagnosed after discharge. Patients with the aforementioned risk
factors may benefit from pharmacologic thromboprophylaxis after AAA
repair. Pharmacologic thromboprophylaxis may not be necessary after ELG.
Table I.





1 ASA class 4-5 vs
1-3
2480 19.9 1.77 (1.22-2.55) .002
2 Dyspnea 3049 24.5 1.68 (1.17-2.39) .005
3 Race vs white 10696 85.8 Reference
Black 467 3.7 2.21 (1.18-4.15) .013
Other/unknown 1306 10.5 0.93 (0.51-1.70) .820
4 Recent weight
loss  10%








repair 3967 31.8 1.46 (0.93-2.30) .104
Intraoperative
transfusion PRBCs
vs none 8551 68.6 Reference
1-2 U 2200 17.6 1.23 (0.73-2.08) .430
3-4 U 978 7.8 1.48 (0.79-2.79) .221
5 U 740 5.9 2.39 (1.27-4.48) .007
Operative duration vs
 2 hrs 3133 25.1 Reference
2.01-3 hrs 4350 34.9 1.78 (0.95-3.28) .070
3.01-4 hrs 2586 20.7 1.70 (0.87-3.35) .123
 4 hrs 2400 19.2 2.33 (1.18-4.59) .014
Wound class not clean 320 2.6 2.01 (1.03-3.94) .041
Thrombolytic Therapy For Significant Pulmonary Emboli
G. Purdy1, H. Mckeever2, T. Khoury3, 1Shawnee State University, Ports-
mouth, Ohio, 2Ohio University College of Osteopathic Medicine, Athens,
Ohio, 3Southern Ohio Surgical Associates, Portsmouth, Ohio
Background: This study is a retrospective review of the treatment of
patients with significant pulmonary emboli (PE) with thrombolytic therapy
in a rural setting hospital. Significant PE is defined as a patient with
hypoxemia  right ventricular strain  hemodynamic compromise. Long-
term studies with emphasis on recurrent deep vein thrombosis was assessed
as well. Patients studied were in the interval of 2000-2010. Records prior to
2000 were not available.
Methods: To review initial thrombolytic therapy, operative reports
were interpreted and evaluated to determine therapy implemented, and if
complete or partial lysis of emboli was achieved. For long-term studies
annual venous duplexes were assessed.
Results: Records from 2000-2010 showed that 51 patients were
treated with thrombolytic therapy. Of those patients, 7 received Urokinase
(drip ranges between 100,000 - 200,000 units/hour), 44 received TPA
(drip ranges between 0.5 - 2 mg/hour). The majority of patients were
dripped via the Unifuse catheter; recently the EKOS catheter has been
implemented upon which 9 out of 51 patients received. Thirty-five out of 51
patients received vena cava filters. Three patients received mechanical lysis
with the Angiojet Device. All patients were on a heparin drip protocol
systematically while on lytic therapy. The average drip duration for treatment
ranged between 12 hours and 24 hours. The average drip duration for TPA
was 24.23 hours for bilateral treatment with a standard deviation of 21.68
hours. The average for Urokinase was 16.57 hours with a standard deviation
of  4.47 hours. Patients who received TPA and EKOS adjunct averaged
14.44 hours. The study showed no procedural mortalities and no deaths at
30 days prior to therapy. Fifty-three percent of patients had complete lysis,
47% had substantial partial lysis with freedom from supplemental oxygen. All
patients improved hemodynamically. Twelve out of 51 patients required a
blood product during their hospitalization. Nine patients required PRBC, 2
FFP, and 1 with CryoPPT. There were no GI bleeds or retroperitoneal
hematomas. Long-term follow-up to 4 years showed 70% venous reflux in
the common femoral vein. Less than 20% of patients experienced a low
incidence of recurrent deep vein thrombosis while on anti-coagulants.
Conclusions: In conclusion, aggressive thrombolysis in significant PE
is safe with substantial results within 24 hours of therapy and rapid improve-
ment in symptoms over a short duration of therapy.
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